Thus, anti-programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) antibody has been approved for second-line or first-line treatment in melanoma, renal cell carcinoma, head and neck squamous and gastroesophageal cancer [1]. Here, RPL17 is linked to melanoma.